Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.

Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, Baum SJ, Bourbon M, Carrié A, Cuchel M, de Ferranti SD, Defesche JC, Freiberger T, Hershberger RE, Hovingh GK, Karayan L, Kastelein JJP, Kindt I, Lane SR, Leigh SE, Linton MF, Mata P, Neal WA, Nordestgaard BG, Santos RD, Harada-Shiba M, Sijbrands EJ, Stitziel NO, Yamashita S, Wilemon KA, Ledbetter DH, Rader DJ; Convened by the Familial Hypercholesterolemia Foundation.

J Am Coll Cardiol. 2018 Aug 7;72(6):662-680. doi: 10.1016/j.jacc.2018.05.044. Review.

PMID:
30071997
2.

Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia.

Hartgers ML, Defesche JC, Langslet G, Hopkins PN, Kastelein JJP, Baccara-Dinet MT, Seiz W, Hamon S, Banerjee P, Stefanutti C.

J Clin Lipidol. 2018 Mar - Apr;12(2):390-396.e8. doi: 10.1016/j.jacl.2017.12.008. Epub 2017 Dec 28.

3.

Familial hypercholesterolaemia.

Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS.

Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi: 10.1038/nrdp.2017.93. Review.

PMID:
29219151
4.

Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia.

Defesche JC, Stefanutti C, Langslet G, Hopkins PN, Seiz W, Baccara-Dinet MT, Hamon SC, Banerjee P, Kastelein JJP.

J Clin Lipidol. 2017 Nov - Dec;11(6):1338-1346.e7. doi: 10.1016/j.jacl.2017.08.016. Epub 2017 Sep 4.

5.

Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia.

Sjouke B, Yahya R, Tanck MWT, Defesche JC, de Graaf J, Wiegman A, Kastelein JJP, Mulder MT, Hovingh GK, Roeters van Lennep JE.

J Clin Lipidol. 2017 Mar - Apr;11(2):507-514. doi: 10.1016/j.jacl.2017.02.010. Epub 2017 Feb 27.

PMID:
28502508
6.

Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease.

Sjouke B, Defesche JC, Hartgers ML, Wiegman A, Roeters van Lennep JE, Kastelein JJ, Hovingh GK.

J Clin Lipidol. 2016 Nov - Dec;10(6):1462-1469. doi: 10.1016/j.jacl.2016.09.003. Epub 2016 Sep 13.

PMID:
27919364
7.

Ten years of lipoprotein apheresis for familial hypercholesterolemia in Malaysia: A creative approach by a cardiologist in a developing country.

Khoo KL, Page MM, Liew YM, Defesche JC, Watts GF.

J Clin Lipidol. 2016 Sep-Oct;10(5):1188-94. doi: 10.1016/j.jacl.2016.05.006. Epub 2016 May 13.

PMID:
27678436
8.

Children with hypercholesterolemia of unknown cause: Value of genetic risk scores.

Sjouke B, Tanck MWT, Fouchier SW, Defesche JC, Hutten BA, Wiegman A, Kastelein JJP, Hovingh GK.

J Clin Lipidol. 2016 Jul-Aug;10(4):851-859. doi: 10.1016/j.jacl.2016.02.017. Epub 2016 Mar 21.

PMID:
27578116
9.

Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia.

Sjouke B, Defesche JC, de Randamie JSE, Wiegman A, Fouchier SW, Hovingh GK.

Atherosclerosis. 2016 Aug;251:263-265. doi: 10.1016/j.atherosclerosis.2016.07.008. Epub 2016 Jul 9.

10.

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, Baum SJ, Catapano AL, Chapman MJ, Defesche JC, Folco E, Freiberger T, Genest J, Hovingh GK, Harada-Shiba M, Humphries SE, Jackson AS, Mata P, Moriarty PM, Raal FJ, Al-Rasadi K, Ray KK, Reiner Z, Sijbrands EJ, Yamashita S; International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.

Lancet Diabetes Endocrinol. 2016 Oct;4(10):850-61. doi: 10.1016/S2213-8587(16)30041-9. Epub 2016 May 27. Review.

11.

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.

Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjærg-Hansen A, Wiklund O; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2015 Sep 21;36(36):2425-37. doi: 10.1093/eurheartj/ehv157. Epub 2015 May 25. Review.

12.

In memoriam: Dato Dr Khoo Kah-Lin--obituary.

Defesche JC, Livingston M.

Atherosclerosis. 2015 Mar;239(1):287. No abstract available.

PMID:
25830181
13.

Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.

Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK.

JAMA. 2015 Mar 10;313(10):1029-36. doi: 10.1001/jama.2015.1206.

PMID:
25756439
14.

[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society].

Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjaerg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; Avrupa Ateroskleroz Derneği Ailevi Hiperkolesterolemi Uzlaşi Paneli.

Turk Kardiyol Dern Ars. 2015 Mar;43 Suppl 1:1-14. Turkish. No abstract available.

15.

Current novel-gene-finding strategy for autosomal-dominant hypercholesterolaemia needs refinement.

Fouchier SW, Hutten BA, Defesche JC.

J Med Genet. 2015 Feb;52(2):80-4. doi: 10.1136/jmedgenet-2014-102653. Epub 2014 Nov 20.

PMID:
25412742
16.

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.

Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjærg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia.

Eur Heart J. 2014 Aug 21;35(32):2146-57. doi: 10.1093/eurheartj/ehu274. Epub 2014 Jul 22.

17.

Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia.

Fouchier SW, Dallinga-Thie GM, Meijers JC, Zelcer N, Kastelein JJ, Defesche JC, Hovingh GK.

Circ Res. 2014 Aug 29;115(6):552-5. doi: 10.1161/CIRCRESAHA.115.304660. Epub 2014 Jul 17.

PMID:
25035151
18.

Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach.

Versmissen J, Oosterveer DM, Yazdanpanah M, Dehghan A, Hólm H, Erdman J, Aulchenko YS, Thorleifsson G, Schunkert H, Huijgen R, Vongpromek R, Uitterlinden AG, Defesche JC, van Duijn CM, Mulder M, Dadd T, Karlsson HD, Ordovas J, Kindt I, Jarman A, Hofman A, van Vark-van der Zee L, Blommesteijn-Touw AC, Kwekkeboom J, Liem AH, van der Ouderaa FJ, Calandra S, Bertolini S, Averna M, Langslet G, Ose L, Ros E, Almagro F, de Leeuw PW, Civeira F, Masana L, Pintó X, Simoons ML, Schinkel AF, Green MR, Zwinderman AH, Johnson KJ, Schaefer A, Neil A, Witteman JC, Humphries SE, Kastelein JJ, Sijbrands EJ.

Eur J Hum Genet. 2015 Mar;23(3):381-7. doi: 10.1038/ejhg.2014.101. Epub 2014 Jun 11.

19.

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.

Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, Roeters van Lennep JE, Stalenhoef AF, Wiegman A, de Graaf J, Fouchier SW, Kastelein JJ, Hovingh GK.

Eur Heart J. 2015 Mar 1;36(9):560-5. doi: 10.1093/eurheartj/ehu058. Epub 2014 Feb 28.

PMID:
24585268
20.

Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia.

Stitziel NO, Fouchier SW, Sjouke B, Peloso GM, Moscoso AM, Auer PL, Goel A, Gigante B, Barnes TA, Melander O, Orho-Melander M, Duga S, Sivapalaratnam S, Nikpay M, Martinelli N, Girelli D, Jackson RD, Kooperberg C, Lange LA, Ardissino D, McPherson R, Farrall M, Watkins H, Reilly MP, Rader DJ, de Faire U, Schunkert H, Erdmann J, Samani NJ, Charnas L, Altshuler D, Gabriel S, Kastelein JJ, Defesche JC, Nederveen AJ, Kathiresan S, Hovingh GK; National Heart, Lung, and Blood Institute GO Exome Sequencing Project.

Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2909-14. doi: 10.1161/ATVBAHA.113.302426. Epub 2013 Sep 26.

21.

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel.

Eur Heart J. 2013 Dec;34(45):3478-90a. doi: 10.1093/eurheartj/eht273. Epub 2013 Aug 15.

22.

Quality assessment of the genetic test for familial hypercholesterolemia in the Netherlands.

Kindt I, Huijgen R, Boekel M, van der Gaag KJ, Defesche JC, Kastelein JJ, de Knijff P.

Cholesterol. 2013;2013:531658. doi: 10.1155/2013/531658. Epub 2013 Jul 8.

23.

Lysosomal acid lipase A and the hypercholesterolaemic phenotype.

Fouchier SW, Defesche JC.

Curr Opin Lipidol. 2013 Aug;24(4):332-8. doi: 10.1097/MOL.0b013e328361f6c6. Review.

PMID:
23652569
24.

A DNA microarray for the detection of point mutations and copy number variation causing familial hypercholesterolemia in Europe.

Stef MA, Palacios L, Olano-Martín E, Foe-A-Man C, van de Kerkhof L, Klaaijsen LN, Molano A, Schuurman EJ, Tejedor D, Defesche JC.

J Mol Diagn. 2013 May;15(3):362-72. doi: 10.1016/j.jmoldx.2013.01.005. Epub 2013 Mar 26.

PMID:
23537714
25.

Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein.

Sorrentino V, Fouchier SW, Motazacker MM, Nelson JK, Defesche JC, Dallinga-Thie GM, Kastelein JJ, Kees Hovingh G, Zelcer N.

Eur Heart J. 2013 May;34(17):1292-7. doi: 10.1093/eurheartj/ehs472. Epub 2013 Jan 16.

PMID:
23324548
26.

Low-density lipoprotein receptor mutations generate synthetic genome-wide associations.

Oosterveer DM, Versmissen J, Defesche JC, Sivapalaratnam S, Yazdanpanah M, Mulder M, van der Zee L, Uitterlinden AG, van Duijn CM, Hofman A, Kastelein JJ, Aulchenko YS, Sijbrands EJ.

Eur J Hum Genet. 2013 May;21(5):563-6. doi: 10.1038/ejhg.2012.207. Epub 2012 Sep 12.

27.

Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia.

Motazacker MM, Pirruccello J, Huijgen R, Do R, Gabriel S, Peter J, Kuivenhoven JA, Defesche JC, Kastelein JJ, Hovingh GK, Zelcer N, Kathiresan S, Fouchier SW.

Eur Heart J. 2012 Jun;33(11):1360-6. doi: 10.1093/eurheartj/ehs010. Epub 2012 Mar 8.

PMID:
22408029
28.
29.

Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.

Huijgen R, Sjouke B, Vis K, de Randamie JS, Defesche JC, Kastelein JJ, Hovingh GK, Fouchier SW.

Hum Mutat. 2012 Feb;33(2):448-55. doi: 10.1002/humu.21660. Epub 2011 Dec 22.

PMID:
22095935
30.

Apolipoprotein isoform E4 does not increase coronary heart disease risk in carriers of low-density lipoprotein receptor mutations.

Versmissen J, Oosterveer DM, Hoekstra M, Out R, Berbée JF, Blommesteijn-Touw AC, van Vark-van der Zee L, Vongpromek R, Vanmierlo T, Defesche JC, Mulder M, Kastelein JJ, Sijbrands EJ.

Circ Cardiovasc Genet. 2011 Dec;4(6):655-60. doi: 10.1161/CIRCGENETICS.111.959858. Epub 2011 Oct 18.

PMID:
22010136
31.

Maternal inheritance of familial hypercholesterolemia caused by the V408M low-density lipoprotein receptor mutation increases mortality.

Versmissen J, Botden IP, Huijgen R, Oosterveer DM, Defesche JC, Heil TC, Muntz A, Langendonk JG, Schinkel AF, Kastelein JJ, Sijbrands EJ.

Atherosclerosis. 2011 Dec;219(2):690-3. doi: 10.1016/j.atherosclerosis.2011.08.039. Epub 2011 Aug 31.

32.

High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutations.

Holleboom AG, Kuivenhoven JA, Peelman F, Schimmel AW, Peter J, Defesche JC, Kastelein JJ, Hovingh GK, Stroes ES, Motazacker MM.

Hum Mutat. 2011 Nov;32(11):1290-8. doi: 10.1002/humu.21578. Epub 2011 Sep 23.

PMID:
21901787
33.

Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children.

van der Graaf A, Avis HJ, Kusters DM, Vissers MN, Hutten BA, Defesche JC, Huijgen R, Fouchier SW, Wijburg FA, Kastelein JJ, Wiegman A.

Circulation. 2011 Mar 22;123(11):1167-73. doi: 10.1161/CIRCULATIONAHA.110.979450. Epub 2011 Mar 7.

PMID:
21382890
34.

Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin.

Alipour A, Cabezas MC, Elte JW, Vallvé JC, Ribalta J, Zwinderman AH, Defesche JC, Jukema JW.

Atherosclerosis. 2011 Mar;215(1):125-9. doi: 10.1016/j.atherosclerosis.2010.11.041. Epub 2010 Dec 8.

PMID:
21211797
35.

Defining the challenges of FH screening for familial hypercholesterolemia.

Defesche JC.

J Clin Lipidol. 2010 Sep-Oct;4(5):338-41. doi: 10.1016/j.jacl.2010.08.022.

PMID:
21122674
36.

A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients.

Versmissen J, Oosterveer DM, Yazdanpanah M, Mulder M, Dehghan A, Defesche JC, Kastelein JJ, Sijbrands EJ.

Eur Heart J. 2011 Feb;32(4):469-75. doi: 10.1093/eurheartj/ehq208. Epub 2010 Jul 1.

PMID:
20595220
37.

Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia.

Huijgen R, Kindt I, Fouchier SW, Defesche JC, Hutten BA, Kastelein JJ, Vissers MN.

Hum Mutat. 2010 Jun;31(6):752-60. doi: 10.1002/humu.21258.

PMID:
20506408
38.

The risk of tendon xanthomas in familial hypercholesterolaemia is influenced by variation in genes of the reverse cholesterol transport pathway and the low-density lipoprotein oxidation pathway.

Oosterveer DM, Versmissen J, Yazdanpanah M, Defesche JC, Kastelein JJ, Sijbrands EJ.

Eur Heart J. 2010 Apr;31(8):1007-12. doi: 10.1093/eurheartj/ehp538. Epub 2009 Dec 16.

PMID:
20019024
39.

5-Lipoxygenase activating protein (ALOX5AP) gene variants associate with the presence of xanthomas in familial hypercholesterolemia.

Oosterveer DM, Versmissen J, Yazdanpanah M, van der Net JB, Defesche JC, Kastelein JJ, Sijbrands EJ.

Atherosclerosis. 2009 Sep;206(1):223-7. doi: 10.1016/j.atherosclerosis.2009.02.019. Epub 2009 Feb 25.

PMID:
19361804
40.

Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform.

Alonso R, Defesche JC, Tejedor D, Castillo S, Stef M, Mata N, Gomez-Enterria P, Martinez-Faedo C, Forga L, Mata P.

Clin Biochem. 2009 Jun;42(9):899-903. doi: 10.1016/j.clinbiochem.2009.01.017. Epub 2009 Feb 6.

PMID:
19318025
41.

Effects of intronic mutations in the LDLR gene on pre-mRNA splicing: Comparison of wet-lab and bioinformatics analyses.

Holla ØL, Nakken S, Mattingsdal M, Ranheim T, Berge KE, Defesche JC, Leren TP.

Mol Genet Metab. 2009 Apr;96(4):245-52. doi: 10.1016/j.ymgme.2008.12.014. Epub 2009 Feb 10.

PMID:
19208450
42.

Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia.

van der Net JB, Janssens AC, Defesche JC, Kastelein JJ, Sijbrands EJ, Steyerberg EW.

Am J Cardiol. 2009 Feb 1;103(3):375-80. doi: 10.1016/j.amjcard.2008.09.093. Epub 2008 Nov 21.

PMID:
19166692
43.

Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia.

Koeijvoets KC, Mooijaart SP, Dallinga-Thie GM, Defesche JC, Steyerberg EW, Westendorp RG, Kastelein JJ, van Hagen PM, Sijbrands EJ.

Eur Heart J. 2009 Mar;30(5):618-23. doi: 10.1093/eurheartj/ehn568. Epub 2008 Dec 19.

PMID:
19098018
44.

Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia.

Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, Araujo L, Vohra Y, Defesche JC, Wilson JM, Rader DJ.

Am J Cardiol. 2008 Dec 1;102(11):1438-43. doi: 10.1016/j.amjcard.2008.07.035. Epub 2008 Sep 11.

PMID:
19026292
45.

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.

Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ.

BMJ. 2008 Nov 11;337:a2423. doi: 10.1136/bmj.a2423.

46.

Two common haplotypes of the glucocorticoid receptor gene are associated with increased susceptibility to cardiovascular disease in men with familial hypercholesterolemia.

Koeijvoets KC, van der Net JB, van Rossum EF, Steyerberg EW, Defesche JC, Kastelein JJ, Lamberts SW, Sijbrands EJ.

J Clin Endocrinol Metab. 2008 Dec;93(12):4902-8. doi: 10.1210/jc.2008-0813. Epub 2008 Sep 23.

PMID:
18812484
47.

Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and coronary heart disease risk in familial hypercholesterolemia.

van der Net JB, Versmissen J, Oosterveer DM, Defesche JC, Yazdanpanah M, Aouizerat BE, Steyerberg EW, Malloy MJ, Pullinger CR, Kane JP, Kastelein JJ, Sijbrands EJ.

Atherosclerosis. 2009 Apr;203(2):472-8. doi: 10.1016/j.atherosclerosis.2008.07.025. Epub 2008 Aug 5.

PMID:
18775537
48.

Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia.

van der Net JB, Oosterveer DM, Versmissen J, Defesche JC, Yazdanpanah M, Aouizerat BE, Steyerberg EW, Malloy MJ, Pullinger CR, Kastelein JJ, Kane JP, Sijbrands EJ.

Eur Heart J. 2008 Sep;29(18):2195-201. doi: 10.1093/eurheartj/ehn303. Epub 2008 Jul 3.

49.

Familial defective apolipoprotein B and familial hypobetalipoproteinemia in one family: two neutralizing mutations.

van der Graaf A, Fouchier SW, Vissers MN, Defesche JC, Wiegman A, Sankatsing RR, Hutten BA, Trip MD, Kastelein JJ.

Ann Intern Med. 2008 May 6;148(9):712-4. No abstract available.

PMID:
18458293
50.

Gene-load score of the renin-angiotensin-aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia.

van der Net JB, van Etten J, Yazdanpanah M, Dallinga-Thie GM, Kastelein JJ, Defesche JC, Koopmans RP, Steyerberg EW, Sijbrands EJ.

Eur Heart J. 2008 Jun;29(11):1370-6. doi: 10.1093/eurheartj/ehn154. Epub 2008 Apr 14.

PMID:
18413308

Supplemental Content

Loading ...
Support Center